Based in New York City, New York, Ventrus Biosciences, Inc. (VTUS), is a development stage specialty pharmaceutical company focused on late stage drugs for gastrointestinal disorders. The 40M market cap company is developing two product candidates:
- Diltiazem cream (VEN 307), a topical treatment for the relief of pain associated with anal fissures; and
- Phenylephrine gel (VEN 308) for the treatment of fecal incontinence associated with ileal pouch anal anastomosis.
Many investors gave up on Ventrus after the company's lead product, iferanserin (VEN 309), a new topical treatment of hemorrhoids failed a Phase 3 trial. There were high hopes that the drug would be a blockbuster for Ventrus because there are...